I
iSpecimen
Marketplace for human biospecimens, providing researchers with the samples they need from the patients they want
About iSpecimen
iSpecimen operates an innovative platform that connects researchers with a diverse network of biospecimen providers, facilitating the acquisition of high-quality biological samples essential for medical research and development. Serving academic institutions, pharmaceutical companies, and diagnostic labs, iSpecimen operates in the life sciences and healthcare markets. The business model revolves around a marketplace approach, where researchers can search, request, and obtain biospecimens from various providers. Revenue is generated through transaction fees and service charges for sample procurement and data management. The platform ensures compliance with regulatory standards and offers a streamlined process for both researchers and providers, enhancing the efficiency of medical research.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2012
- Headquarters
- Woburn, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
MassChallenge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about iSpecimen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iSpecimen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.